SCHEMBL6017701

SCHEMBL6017701

Cn1c(-c2c(F)cccc2F)nc(C(=O)NCc2ccc3c(c2)OCO3)c(O)c1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
HPGD P15428 3/20 0.51
TSHR P16473 2/20 0.51
KMT2A Q03164 5/20 0.51
MEN1 O00255 4/20 0.51
HSD17B10 Q99714 3/20 0.51
KDM4E B2RXH2 2/20 0.51
TP53 P04637 2/20 0.51
HTT P42858 2/20 0.51
USP2 O75604 1/20 0.51
CYP1A2 P05177 1/20 0.51
POLB P06746 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
CASP7 P55210 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.50
LMNA P02545 2/20 0.50
MAPK1 P28482 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6017839 0.87 SCD (0.46) KMT2AMEN1SMN1; SMN2
SCHEMBL6017737 0.86 KCNE1 (0.44) KMT2AMEN1MMP13SMN1; SMN2
SCHEMBL6017708 0.85 KCNE1 (0.48) ALDH1A1KMT2AMEN1TP53POLB
SCHEMBL6017627 0.85 KCNE1 (0.54) KMT2AMEN1TP53POLBCYP2C9
SCHEMBL6018223 0.84 CNR1 (0.48) ALDH1A1HPGDKMT2AMEN1
SCHEMBL6017779 0.83 KCNE1 (0.42) KMT2ASMN1; SMN2
SCHEMBL6018572 0.83 KMT2A (0.49) KMT2AMEN1TP53LMNASMN1; SMN2
SCHEMBL6018064 0.83 KCNE1 (0.44) KMT2AMEN1SMN1; SMN2
SCHEMBL6017870 0.81 KCNE1 (0.47) ALDH1A1KMT2AMEN1KDM4EPOLB
SCHEMBL6017734 0.80 TACR1 (0.50) KDM4EHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY 2004-11-18 US claimed
US-7037908-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2006-05-02 US disclosed
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY 2004-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex DUT, CDK6, TYMS ALDH1A1 633/4885HPGD 1117/4885TSHR 4295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.